Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients | Zendy

Lorenzo Gallon | Zendy; Pranav Dalal | Zendy; Shah | Zendy; Chhara | Zendy

Open Access

Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients

Author(s) -

Lorenzo Gallon,

Pranav Dalal,

Shah,

Chhara

Publication year - 2010

Publication title -

international journal of nephrology and renovascular disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.846

H-Index - 27

ISSN - 1178-7058

DOI - 10.2147/ijnrd.s7044

Subject(s) - tacrolimus , medicine , immunosuppression , mycophenolate , organ transplantation , dosing , kidney transplantation , transplantation , mycophenolic acid , intensive care medicine , urology , pharmacology

Several new medications are now available for immunosuppression in the kidney transplant field. Tacrolimus and mycophenolate mofetil were first introduced for immunosuppression in renal transplantation in the mid 1990s. Since then, the combination of tacrolimus and mycophenolate mofetil has been evaluated in numerous clinical trials. The outcomes of these trials have varied due to differences in induction and/or maintenance therapy, drug dosing and monitoring protocols, and study design. The aim of this review is to analyze the literature critically and to provide an overview of tacrolimus and mycophenolate mofetil combination therapy in renal transplantation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research